Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organs.

ABSTRACT:

Objective

This study aimed to determine and compare the tumor shrinkage rate and its durability by enfortumab vedotin treatment between primary urothelial carcinoma and metastatic organs.

Methods

We retrospectively evaluated the tumor shrinkage rate in 39 Japanese patients treated with enfortumab vedotin for advanced urothelial carcinoma. We also evaluated the periods of tumor shrinkage maintenance (the period when best response was maintained) and regrowth (the period from best response to tumor growth confirmation) between primary and metastatic organs.

Results

Measurable metastatic organs included the lung in 17, lymph node in 22, liver in 6, and bone in 5 cases. Primary lesion was detected in 20 cases. The mean tumor shrinkage rates for lung, lymph node, liver, an

SUBMITTER: Ikarashi D 

PROVIDER: S-EPMC11813790 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature